We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 21

Universities abroad experiment with no-fee licensing to drive biotech partnerships
  • Shook Hardy & Bacon LLP
  • USA, Australia, Canada, European Union, United Kingdom
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies


EU medical device manufacturers address plan to change regulatory directives
  • Shook Hardy & Bacon LLP
  • European Union
  • February 8 2013

Eucomed, an organization that represents the interests of the European medical device industry, has issued a position paper that assesses a number of


EC approves first gene therapy medicine in western world
  • Shook Hardy & Bacon LLP
  • European Union
  • November 15 2012

The European Commission has given final approval to uniQure’s gene therapy Glybera for the treatment of lipoprotein lipase deficiency patients with recurring acute pancreatitis


EU Medicines Agency plans to appeal interim rulings on release of clinical trial data
  • Shook Hardy & Bacon LLP
  • European Union
  • May 16 2013

According to a news source, European Medicines Agency (EMA) Director Guido Rasi intends to appeal interim rulings recently issued by the European


Report suggests Europe could become marine biotech leader by 2020
  • Shook Hardy & Bacon LLP
  • European Union
  • January 13 2011

The Marine Board of the European Science Foundation has released a report that suggests Europe could become a global leader in marine biotechnology by 2020, particularly by cultivating microalgae for fuel


European nations sign MOU to manage life-science information
  • Shook Hardy & Bacon LLP
  • European Union
  • September 22 2011

Denmark, Finland, the Netherlands, Sweden, and the United Kingdom have reportedly signed a memorandum of understanding (MOU) with the European Molecular Biology Laboratory to create an infrastructure that would both manage and safeguard life-science data generated by publicly funded research


EU Court of Justice interprets law extending patent protection for medicinal products
  • Shook Hardy & Bacon LLP
  • European Union
  • December 15 2011

The Court of Justice of the European Union (ECJ) has issued two rulings interpreting EU law at the request of British courts addressing whether drug makers can obtain a supplementary protection certificate (SPC), which extends patent protection, for products with active ingredients additional to those specified in the original patent


European Medicines Agency seeks feedback on biosimilars guideline
  • Shook Hardy & Bacon LLP
  • European Union
  • December 15 2011

The European Medicines Agency has issued for public comment a “Concept paper on the revision of the guideline on similar biological medicinal product.”


EU legal services opinion could upset proposed GM laws
  • Shook Hardy & Bacon LLP
  • European Union
  • November 18 2010

According to media sources, the EU Council of Ministers' Legal Service has expressed "strong doubts" about the feasibility of a proposal that would allow individual member states to set their own policies for regulating genetically modified (GM) crops


EU regulators charge pharma companies with antitrust violations in pay-for-delay deals
  • Shook Hardy & Bacon LLP
  • European Union
  • August 2 2012

The European Commission (EC) has reportedly charged nine pharmaceutical companies with breaches of European Union (EU) antitrust rules for entering pay-for-delay deals with generic competitors